EnteroMedics and its risky obesity device, the latest victims of the IPO haircut
(UPDATED: See below.)
(NOTE: This item was originally published as part of today’s life-sciences briefing.)
EnteroMedics, a St. Paul, Minn., device maker working on a neuromodulation implant for treating obesity, slashed its expected IPO pricing by half, lowering it to a range of $8 to $9 instead of… Continue Reading
Life sciences briefing: Wednesday, Nov. 14, 2007
Featured companies: Advanced Bio-Surfaces, Ambit Biosciences, EnteroMedics, Molecular Vision, Skyline Ventures
UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here.
Skyline Ventures raises $350M life-sciences fund — Skyline Ventures, a Palo Alto, Calif., VC firm, closed a $350 million fund… Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech… Continue Reading
EnteroMedics plans $86M IPO for obesity-control implants
EnteroMedics, a St. Paul, Minn., developer of obesity-treatment implants, filed to raise up to $86.25 million in an IPO. Its S-1 filing with the SEC is here.
The company is developing a neuromodulation implant called VBLOC that is designed to intermittently disrupt signals sent along the… Continue Reading